Sustainable rare diseases business and drug access: No time for misconceptions

Orphanet Journal of Rare Diseases

Volumn 8, Issue 1, 2013, Pages 1-9

  Rollet, Pierrick ^a   Lemoine, Adrien ^a   Dunoyer, Marc ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ORPHAN DRUG;

BUDGET; CAPITAL; COMMERCIAL PHENOMENA; DRUG COST; DRUG INDUSTRY; DRUG MARKETING; EUROPE; HEALTH CARE ACCESS; HEALTH CARE COST; HEALTH CARE POLICY; HUMAN; INVESTMENT; PRODUCTIVITY; RARE DISEASE; REVIEW; SIMULATION; THERAPEUTIC MISCONCEPTION;

EID: 84881482075     PISSN: None     EISSN: 17501172     Source Type: Journal    
DOI: 10.1186/1750-1172-8-109     Document Type: Review

References (33)

1. Why rare diseases are an important medical and social issue. Schieppati A, Henter JI, Daina E, et al. Lancet 2008 371 2039 2041 10.1016/S0140-6736(08) 60872-7 18555915 (Pubitemid 351799861)
2. Eurordiscare report, "the voice of 12 000 patients Experiences and Expectations of Rare Disease Patients on Diagnosis and Care in Europe.
3. Experiences of Rare Diseases, An Insight from Patients and Families Genetic alliance UK, Rare diseases UK report. 2010
4. The cost of Muscular Dystrophy", Report by Access Economics Pty Limited for the Muscular Dystrophy Association 2007 23888335
5. OHE Consulting, Assessment of the Impact of Orphan Medicinal Products (OMPs) on the European Economy and Society 2010
6. Is it time to revisit orphan drug policies. C McCabe, BMJ 2010 341 25
7. Tambuyzer E, "Rare diseases, orphan drugs and their regulation: questions and misconceptions" Nature Reviews Drug Discovery | AOP. 2010
8. Paying for the Orphan Drug System: break or bend? Is it time for a new evaluation system for payers in Europe to take account of new rare disease treatments. Wills Hughes W, Orphanet J Rare Dis 2012 7 74 10.1186/1750-1172-7-74 23013790
9. Country drug public list prices from: France, Official Journal of the French Republic (JORF), Germany- Informationsstelle für Arzneispezialitäten (IFA) via ABDATA, Italy- Italian Medicines Agency (AIFA) via Farmadati, Spain- Spanish Pharmaceutical Association (BOT) UK- National Health Service (NHS) via Drug Tariff; Chemist & Druggist. UK- National Health Service (NHS) via Drug Tariff; Chemist & Druggist
10. EPAR, http://www.ema.europa.eu
11. Gross national income per capita Atlas method and PPP. 2010 http://www.worldbank.org
12. Dr Michael Barry ISPOR November 2012, "IP2: is there scope for more harmonization of procedures for assessing orphan drugs in Europe http://www.ispor.org
13. what is wrong with orphan drug policies. Coté A, Value Health 2012 15 1185 1191 10.1016/j.jval.2012.09.004 23244823
14. The tiger in the fiscal room, Beware the increasing cost and number of orphan drugs
15. Schey C, Estimating the budget impact of orphan medicines in Europe 2010 2020
16. médicaments orphelins, un dispositif à renforcer. AFM report, Février 2011 23914328
17. Global Spending on Orphan Drugs in France, Germany, the UK, Italy and Spain during 2007. Orofino J, Appl Health Econ Health Policy 2010 8 5 301 315 10.2165/11531880-000000000-00000 20804223
18. A comparative study of European rare disease and orphan drug markets. Denis A, Mergaert L, Fostier C, Cleemput I, Simoens S, Health Policy 2010 97 173 179 10.1016/j.healthpol.2010.05.017 20800761
19. Linking payment to health outcomes: A taxonomy and examination of performance-based reimbursement schemes between healthcare payers and manufacturers. Carlson JJ, Health Policy 2010 96 179 190 10.1016/j.healthpol. 2010.02.005 20226559
20. What principles should govern the use of managed entry agreements? Klemp M, Int J Technol Assess Health Care 2011 27 1 77 83 10.1017/S0266462310001297 21262072
21. Human Medicines Development Evaluation, Committee for Orphan Medicinal Products (COMP) meeting report on the review of applications for orphan designation United Kingdom: Europian Medicines Agency 2013 http://www.fda.gov/ www.ema.europa.eu
22. Evaluate Pharma, Orphan Drug report 2013
23. Kiran N, Meekings, Orphan drug development: an economically viable strategy for biopharma R&D", Drug Discovery Today 2012 22366309
24. Jorge Mestre F, The R&D cost of a new medicine OHE report. 2012 20025486
25. How to improve R&D productivity: the pharmaceutical industry's grand challenge. Paul S, Nat Rev Drug Discov 2010 9 203 214 20168317
26. factors associated with success of market authorization applications for pharmaceutical drugs submitted to the European Medicines agency. Regnstrom J, Eur J Clin Pharmacol 2010 66 39 48 10.1007/s00228-009-0756-y 19936724
27. productivity in pharmaceutical-biotechnology R&D: the role of expererience and alliances. Danzon P, J Health Econ 2005 24 317 339 10.1016/j.jhealeco.2004.09.006 15721048 (Pubitemid 40249770)
28. Orfali M, Raising Orphans: How Clinical Development Programs of Drugs for Rare and Common Diseases Are Different Clinical pharmacology & Therapeutics. 2012
29. financial reports of Actelion (2012), Alexion (2012), Bio Marin (2012), Dyax (2012), Enzon (2009),Genzyme (2010), Shire (2012), Sobi (2012), Viropharma (2012), United Therapeutics 2012
30. "the cost of biopharmaceutical R&D, is Biotech different. Di JA, Masi HG, Grabowski, manage decision economics 2007 28 469 479 10.1002/mde.1360
31. Estimated research and development costs of rotavirus vaccines. Light DW, Vaccine 2009 Nov 5 27 47 6627 6633 10.1016/j.vaccine.2009.07.077
32. Jack A, Financial times healthcare uncommon complaints. 2012
33. (EC) No 141/2000 of the European parliament and of the council of 16 December 1999 on Orphan Medicinal products. Official Journal of the European Communities, Regulation 2000 1 22